// App-Quantinova.ai

93 : Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-BEACON Study

Researchers

Presenter

  • Joel Kremer

Principal Investigators

  • Omid Zamani

  • Douglas Schlichting

  • Josef Smolen

  • Arthur Bookman

  • Charles Ludivico

  • Marek Krogulec

  • Li Xie

  • Scott Beattie

  • Alisa Koch

  • Tracy Cardillo

  • Terence Rooney

  • William Macias

Medical Centers

  • Univ of Toronto, Toronto, Canada

Locations

  • Canada

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • High sensitivity C-reactive protein

  • Janus kinase

  • Tumor necrosis factor

Drug/Treatment

  • Baricitinib

Outcome

  • Unknown

Study Design

  • randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved